Abstract

Laminin β4 was recently identified as a structural component of the dermal-epidermal junction and autoantigen of anti-p200 pemphigoid. In this study, we provided further evidence of the pathogenic effect of anti-laminin β4 IgG and identified potential binding partners of laminin β4. We showed that laminin β4 immune complexes led to activation of normal leukocytes and dose-dependent ROS release. Using cryosections of normal skin, we demonstrated that anti-laminin β4 patient serum IgG but not anti-laminin γ1 IgG, which are also detectable in patients with anti-p200 pemphigoid, cause dermal-epidermal separation in the presence of leukocytes. Proximity ligation assay and indirect immunofluorescence staining suggested that laminin β4 localizes closely to laminin α3 and γ2 in primary keratinocytes. Subsequent coimmunoprecipitation experiments using epidermal extracts confirmed the interaction of laminin β4 with the α3 and γ2 chains and indicated additional affinity to laminin γ1. The laminin β4-α3/β4-γ1 protein complexes were also detected using mass spectrometry. In conclusion, this study showed that anti-laminin β4 IgG can exert tissue damage in the skin, supporting their pathogenic role in anti-p200 pemphigoid. Our data further provide strong evidence for an interaction of laminin β4 with laminin α3, whereas its association to the laminin γ1 and γ2 chains is ambiguous.

OriginalspracheEnglisch
ZeitschriftThe Journal of investigative dermatology
ISSN0022-202X
PublikationsstatusVeröffentlicht - 2024

Fördermittel

The guarantor of this study was MP. The authors thank the patients who participated in this study and the Holstentor-Privatklinik, L\u00FCbeck for providing skin samples. The authors also thank Stephanie Freyher, Sylvana Schult, and Vanessa Krull of the L\u00FCbeck Institute of Experimental Dermatology for excellent technical assistance. The work was supported by the German Research Foundation through the Schleswig-Holstein Excellence Cluster Precision Medicine in Chronic Inflammation (DFG EXC 2167/1, TI-3 to ES), the CRU 303 Pemphigoid Diseases (to IRK and ES), and the CRC 1526 Pathomechanisms of Antibody-mediated Autoimmunity (to CMH and ES) as well as research grants from the University of L\u00FCbeck (J08-2021 and H01-2023 to MP, J13-2022 to SE, and CS06-2019 to CMH). Conceptualization: MP, SG, ES; Formal Analysis: MP, SE, IRK; Funding Acquisition: MP, ES; Methodology: MP, SG, YW, SE, CMH, SP, BO, FHS, IRK, CR, LK, CH, ES; Investigation: MP, SG, YW, SE, CR, LK, CH; Project Administration: MP, SG, LK, ES; Resources: MMH, SP, BO, FHS, CR, LK, MA, CH, ES; Supervision: MP, SG, ES; Visualization: MP, SG, YW, SE, IRK, CH; Writing \u2013 Original Draft Preparation: MP, SG, ES; Writing \u2013 Review and Editing: MP, SG, YW, SE, CMH, MMH, SP, BO, FHS, IRK, CR, LK, MA, CH, ES The work was supported by the German Research Foundation through the Schleswig-Holstein Excellence Cluster Precision Medicine in Chronic Inflammation (DFG EXC 2167/1, TI-3 to E.S.), the CRU 303 Pemphigoid Diseases (to I.R.K. and E.S.), and the CRC 1526 Pathomechanisms of Antibody-mediated Autoimmunity (to C.M.H. and E.S.) as well as research grants from the University of L\u00FCbeck (J08-2021 and H01-2023 to M.P, J13-2022 to S.E, and CS06-2019 to C.M.H.).

TrägerTrägernummer
Children's Mercy Hospital
Universität zu LübeckCS06-2019, J08-2021, H01-2023, J13-2022
CRU 303 Pemphigoid DiseasesCRC 1526
Deutsche ForschungsgemeinschaftEXC 2167/1, TI-3

    UN SDGs

    Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

    1. SDG 3 – Gesundheit und Wohlergehen
      SDG 3 – Gesundheit und Wohlergehen

    Strategische Forschungsbereiche und Zentren

    • Forschungsschwerpunkt: Infektion und Entzündung - Zentrum für Infektions- und Entzündungsforschung Lübeck (ZIEL)

    DFG-Fachsystematik

    • 2.21-05 Immunologie

    Fingerprint

    Untersuchen Sie die Forschungsthemen von „Anti-Laminin β4 IgG Drives Tissue Damage in Anti-p200 Pemphigoid and Shows Interactions with Laminin α3 and γ1/2 Chains“. Zusammen bilden sie einen einzigartigen Fingerprint.
    • SFB 1526, PANTAU: Pathomechanismen Antikörpervermittelter Autoimmunerkrankungen

      Sadik, C. (Sprecher*in, Koordinator*in), Zillikens, D. (Sprecher*in, Koordinator*in), Scheffold, A. (Projektleiter*in (PI)), Schmidt, E. (Projektleiter*in (PI)), Heine, G. (Projektleiter*in (PI)), Manz, R. (Projektleiter*in (PI)), Köhl, J. (Projektleiter*in (PI)), Ludwig, R. (Projektleiter*in (PI)), Peipp, M. (Projektleiter*in (PI)), Hammers, M. C. (Projektleiter*in (PI)), Verschoor, A. (Projektleiter*in (PI)), Karsten, C. (Projektleiter*in (PI)), Nimmerjahn, F. (Projektleiter*in (PI)), Hutloff, A. (Projektleiter*in (PI)), Ibrahim, S. (Projektleiter*in (PI)), Wettschureck, N. (Projektleiter*in (PI)), Bieber, K. (Projektleiter*in (PI)), Schilf, P. (Projektleiter*in (PI)), Vaeth, M. (Projektleiter*in (PI)), Hirose, M. (Projektleiter*in (PI)), Vaeth, M. (Projektleiter*in (PI)), Baines, J. F. (Projektleiter*in (PI)), Bacher, P. (Projektleiter*in (PI)), Hoffmann, M. (Projektleiter*in (PI)), Busch, H. S. (Projektleiter*in (PI)), Höppner, M. (Projektleiter*in (PI)), Becker, M. (Projektleiter*in (PI)), Holtsche, M. M. (Projektleiter*in (PI)), Fähnrich, A. (Projektleiter*in (PI)), Szymczak, S. (Projektleiter*in (PI)), Murthy, S. (Projektleiter*in (PI)) & Lux, A. (Projektleiter*in (PI))

      01.01.22 → …

      Projekt: DFG VerbundprojekteDFG Sonderforschungsbereiche / Transregios (SFB/TR)

    Zitieren